Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethoglucid
- Development stage
- Unknown
- Lead developer
- AkzoNobel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ethoglucid is a small molecule chemotherapeutic agent in the epoxide class, used as an alkylating antineoplastic agent, particularly for bladder neoplasms. It acts by crosslinking DNA through its epoxy groups, interfering with DNA function and inducing cell cycle arrest and cytotoxicity. It is toxic to hair follicles, the gastrointestinal tract, and the vasculature.
- Brand names
- Epodyl
- Other names
- etoglucideethoglucidetriethylene glycol diglycidyl etherdiglycidyltriethylene glycol1,2-bis[2-(2,3-epoxypropoxy)ethoxy]ethane2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bisoxirane
02
Targets
DNA
Beyond the preview
Go deeper on ethoglucid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethoglucid.